SAGE Therapeutics Inc (SAGE) : Gilder Gagnon Howe Co reduced its stake in SAGE Therapeutics Inc by 7.62% during the most recent quarter end. The investment management company now holds a total of 324,344 shares of SAGE Therapeutics Inc which is valued at $14,274,379 after selling 26,761 shares in SAGE Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.SAGE Therapeutics Inc makes up approximately 0.26% of Gilder Gagnon Howe Co’s portfolio.
Other Hedge Funds, Including , California State Teachers Retirement System boosted its stake in SAGE in the latest quarter, The investment management firm added 22,531 additional shares and now holds a total of 55,542 shares of SAGE Therapeutics Inc which is valued at $2,444,403. SAGE Therapeutics Inc makes up approx 0.01% of California State Teachers Retirement System’s portfolio. Quantitative Systematic Strategies sold out all of its stake in SAGE during the most recent quarter. The investment firm sold 7,280 shares of SAGE which is valued $326,581. Simplex Trading added SAGE to its portfolio by purchasing 27,970 company shares during the most recent quarter which is valued at $1,208,304. SAGE Therapeutics Inc makes up approx 0.15% of Simplex Trading’s portfolio.
SAGE Therapeutics Inc closed down -0.78 points or -1.77% at $43.23 with 4,67,944 shares getting traded on Thursday. Post opening the session at $44.2, the shares hit an intraday low of $42.95 and an intraday high of $44.89 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
Many Wall Street Analysts have commented on SAGE Therapeutics Inc. H.C. Wainwright Initiated SAGE Therapeutics Inc on Jun 23, 2016 to “Buy”, Price Target of the shares are set at $56.Chardan Capital Markets Initiated SAGE Therapeutics Inc on May 24, 2016 to “Sell”, Price Target of the shares are set at $18.
SAGE Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.